Genetic alterations in mTOR signaling have been implicated in metabolic disorders, neurodegeneration, ageing and in various cancer types [45,47]; in particular, dysregulations of mTOR pathway have been detected in 36% of patients with SCLC and have been related to radiation and chemotherapy resistance [47,48]. Here, MTOR is linked to metabolic disease.